Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 52 of 65 · 3097 articles
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Chronic pain affects many people with IBD even after inflammation is controlled, often limiting daily activities and worsening mental health. Understanding that pain can persist without active inflammation highlights the...
If you have IBD, J&J’s ICOTYDE/TREMFYA‑class program could expand oral IL‑23 treatment options for ulcerative colitis and Crohn’s disease and may have implications for perianal fistulizing Crohn’s disease — an area with...
Probiotics like Lactobacillus GG are often considered by families of children with Crohn’s disease. If helpful, they could offer a low-risk adjunct that targets the gut microbiome and barrier function. This pilot study...
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
This trial tests an oral integrin α4β7 inhibitor for Crohn’s disease, a new small-molecule approach aiming to block gut-specific immune cell trafficking similar to existing biologic anti‑integrin drugs. If effective and...
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...
People with Crohn’s disease often have disrupted gut microbiomes; this trial tests a food-based approach (cranberry powder) that could potentially encourage beneficial bacteria and reduce inflammation, which is of direct...
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...
AI could help make assessments (endoscopy, histology, imaging) more objective and combine complex data to better predict disease course—potentially improving personalized care planning for people with IBD.
This study suggests a specific probiotic strain may help reduce colitis in mice by changing the gut microbiome and boosting host phosphatidylcholine production — a pathway that could be relevant to gut barrier repair in...
A new patient-derived “Colon Chip” reproduces key features of Crohn’s disease and ulcerative colitis in the lab and points to fibroblasts as active drivers of inflammation and early cancer-associated changes — insights...
Knowing the makeup and regional distribution of IBD specialists helps identify gaps in care access and guide training or policy efforts to expand specialist capacity in underserved areas.
Researchers exploring new anti-inflammatory or antioxidant compounds for ulcerative colitis may find sanggenol L’s effects on Nrf2/HO-1 and TLR4/p65 signalling of interest. Patients should note this is early-stage,...
FMT and precision microbiota therapies target the gut ecosystem, a modifiable factor in UC. For people with UC, this review explains potential mechanisms, where FMT has shown benefit in trials, and why it is still...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Pouchitis affects a large share of patients after IPAA surgery and causes significant morbidity. Identifying pre-surgery immune, epithelial, or microbial signatures that predict pouchitis could help guide who should get...
A validated human peristaltic intestinal organoid model could make preclinical testing more predictive for drugs affecting gut motility and reduce reliance on animal models.
People with IBD often receive general advice to eat more fiber, but certain purified fibers or fiber-enriched foods may help some people while worsening inflammation in others. Research that teases apart fiber types and...
People with HαT report GI symptoms often labeled IBS; this study aims to test whether intestinal barrier dysfunction and specific food proteins trigger mucosal and mast-cell responses that could explain symptoms. If...
Tertiary lymphoid organs form in IBD and may influence disease course; understanding how lymphatic S1PR1 controls TLOs could reveal new targets to modify intestinal inflammation without broad immunosuppression.
Understanding gene–microbe interactions that drive site-specific disease in very early-onset Crohn’s could reveal why some children develop ileal versus colonic disease and suggest new approaches to prevention or...
Perioperative nutrition could affect recovery after Crohn’s bowel surgery; a trial of Exclusive Enteral Nutrition may show whether a pre- or peri-surgical liquid diet reduces complications and improves outcomes. Patients...
Finding a pathogenic HMBS variant in a child with extensive ulcerative colitis suggests rare genetic conditions (like acute intermittent porphyria) can appear alongside or mimic IBD and might affect symptoms or...
Granulomas are a classic histologic feature of Crohn’s disease, so patients and clinicians may wonder whether their presence predicts worse disease or different treatment needs. This review shows existing studies are...
This study highlights factors—tumor location, age, smoking, and having IBD—that were associated with survival and progression in a Lebanese CRC cohort.
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
Patients and clinics are still deciding how much care can be done remotely. Knowing who prefers in-person versus remote visits helps tailor care so patients receive the visit type they need and want, and supports...
The study identifies a food-derived compound that improved colitis in lab models and acted on JAK/STAT3 signaling and intestinal barrier proteins—pathways relevant to IBD inflammation and mucosal healing.
Biomaterials that directly modify immune responses could offer new localized, targeted ways to treat gut inflammation, potentially reducing reliance on systemic immunosuppressive drugs. This review summarizes preclinical...
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
Identifies a microbiome-derived protein that inhibits a protease linked to epithelial damage in IBD and shows protective effects in lab and mouse models, pointing to a new therapeutic strategy focused on barrier...
This study suggests that subgrouping autoimmune diseases by a Traditional Chinese Medicine phenotype (Dampness ZHENG) corresponds to distinct T‑ and B‑cell receptor patterns.
The study tests a multi-targeted biohybrid that could—if translated—help address inflammation, oxidative stress, and dysbiosis together, a combination that current single-target IBD treatments often do not address.
RIPK proteins are central to cell-death and inflammatory pathways that can damage the intestinal lining in IBD. Understanding them could point to new treatments that more precisely block harmful inflammation while...
Identifies oral microbes that may appear in the gut of people with IBD and PSC, which could help researchers understand disease mechanisms and eventually inform diagnostics or microbiome-targeted strategies.
PSC can progress to cirrhosis and cholangiocarcinoma; circulating multi-omic signatures that track severity and cancer-associated changes could help explain disease biology and lead to biomarkers for risk stratification...
Animal research shows a postbiotic from Enterococcus faecium altered gut barrier markers and the microbiome in chickens; this may be of scientific interest for gut microbiome and adjuvant research but does not imply...
People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which...
This review suggests a new way to think about IBD relapse and disease persistence: persistent changes in innate immune cells (trained immunity) could maintain gut inflammation even when adaptive immune targets are...
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...
A more detailed, reproducible measure of endoscopic inflammation could better reflect total disease burden and reduce variability from human readers. That may matter for monitoring disease activity, judging treatment...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
